MIRA Pharmaceuticals Advances Lead Drug Ketamir-2 to Final Phase 1 Cohort, Targets Fast Track for Phase 2a

summarizeSummary

MIRA Pharmaceuticals announced significant progress for its lead drug candidate, Ketamir-2, by initiating dosing in the final cohort of its Phase 1 trial and outlining plans for a Phase 2a study targeting FDA Fast Track designation.

check_boxKey Events

• Ketamir-2 Phase 1 Progress

  Initiated dosing in the final cohort of the Phase 1 multiple ascending dose (MAD) clinical trial for Ketamir-2, with 50 healthy volunteers already dosed and 6 subjects remaining. Completion is expected by the end of Q1 2026.

• Phase 2a Study & Fast Track Designation

  Finalizing plans for a Phase 2a proof-of-concept study in chemotherapy-induced peripheral neuropathy (CIPN), with anticipated initiation in Q2 2026 and intent to pursue FDA Fast Track designation due to the lack of approved therapies.

• Upcoming Data Presentation & Partnering

  Plans to present Phase 1 data for Ketamir-2 at the American Association for Cancer Research (AACR) Annual Meeting in April 2026 and engage in partnering discussions at the BIO Partnering Investment & Growth Summit in March 2026.

• Preclinical Pipeline Update

  Provided updates on preclinical programs SKNY-1 (weight loss, nicotine addiction) and MIRA-55 (inflammatory pain), aiming for IND-enabling status by year-end 2026.

auto_awesomeAnalysis

This filing provides a comprehensive positive update on MIRA Pharmaceuticals' drug development pipeline, particularly for its lead candidate, Ketamir-2. Advancing to the final cohort of a Phase 1 trial and setting a clear timeline for Phase 2a initiation demonstrates tangible progress. The intent to seek FDA Fast Track designation for chemotherapy-induced peripheral neuropathy (CIPN) is a significant positive, as it could expedite the development and regulatory review process for a condition with unmet medical needs. Upcoming presentations and partnering discussions will increase visibility and potential for future collaborations. The updates on preclinical programs also highlight a broader long-term pipeline. For a company of this size, consistent clinical progress and strategic regulatory planning are crucial for investor confidence and future value creation.